

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 28897

Manuscript Type: CASE REPORT

Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma

Takano M *et al.* Complete response with sorafenib in HCC

Michitoshi Takano, Takashi Kokudo, Yoshihiro Miyazaki, Yumiko Kageyama, Amane Takahashi, Katsumi Amikura, Hirohiko Sakamoto

Michitoshi Takano, Takashi Kokudo, Yoshihiro Miyazaki, Yumiko Kageyama, Amane Takahashi, Katsumi Amikura, Hirohiko Sakamoto,
Division of gastroenterology, Saitama Cancer Center, Kitaadachi-gun, Saitama 362-0806, Japan

Author contributions: Takano M wrote the original manuscript; all authors

Match Overview

1	Internet 220 words crawled on 04-Jul-2016 www.wjgnet.com	14%
2	CrossCheck 26 words Hidenori Kamiyama. "Resection of hepatocellular carcinoma with tumor thrombus of the portal vein after neoadjuvant ..."	2%
3	CrossCheck 20 words Isoda, Susumu, Tamizo Kimura, Kenji Nishimura, Nozomu Yamanaka, Shingo Nakamura, Hiroshi Arino, Masatoshi A	1%

学术搜索

找到约 2,950 条结果 (用时0.09秒)

文章

我的图书馆

时间不限

2016以来

2015以来

2012以来

自定义范围...

按相关性排序

按日期排序

搜索所有网页

中文网页

简体中文网页

包括专利

包含引用

创建快讯

小提示: 只搜索中文(简体)结果, 可在 学术搜索设置 指定搜索语言

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

M Kudo, K Imanaka, N Chida, K Nakachi... - ... Journal of Cancer, 2011 - Elsevier
... c Complete response was defined in the study protocol as 100% tumour shrinkage or necrosis. Full-size ... By the cutoff date of 10th July 2009, 324 progression events (137 in the sorafenib and 187 in the placebo group) were confirmed by the Response Evaluation Committee. ...

被引用次数: 270 相关文章 所有 6 个版本 引用 保存

[HTML] ascopubs.org

Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma

TM Pawlik, DK Reyes, D Cosgrove... - Journal of Clinical ..., 2011 - jco.ascopubs.org
... Complete response, partial response, stable disease, and progressive disease were calculated using both RECIST and EASL criteria. ... rate as evaluated per lesion was 92% to 100%, with an objective response rate of ... Abstract/FREE Full Text. ... Varela M.; Real MI.; Burrel M.; et al. ...

被引用次数: 225 相关文章 所有 11 个版本 引用 保存

Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma

JW Park, YH Koh, HB Kim, HY Kim, S An, JI Choi... - Journal of ..., 2012 - Elsevier
... Full-size table Table options: ... According to the best tumor response based on RECIST criteria, no patient had a complete response (CR), 22 patients had partial ... In the best tumor response based on mRECIST criteria for CR, PR, and SD was 29 patients (58%), 11 patients (22 ...

被引用次数: 98 相关文章 所有 9 个版本 引用 保存

Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study

J Lammer, K Malagari, T Vogl, F Pilleul... - Cardiovascular and ..., 2010 - Springer
... Objective response rate (OR) was defined as complete response plus partial response, and disease ... Supplementary post hoc analyses focused on treatment response and safety were therefore ... used so that the primary endpoint could be assessed using the full MITT population ...

被引用次数: 803 相关文章 所有 24 个版本 引用 保存

[HTML] springer.com

[HTML] Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival

[HTML] wiley.com

全部 图片 新闻 视频 购物 更多 ▾ 搜索工具

找到约 45,900 条结果 (用时 0.72 秒)

Google 学术 : Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma

... patients with unresectable hepatocellular carcinoma - Kudo - 被引用次数 : 272

... with drug-eluting beads for hepatocellular carcinoma - Pawlik - 被引用次数 : 225

... in patients with unresectable hepatocellular carcinoma - Park - 被引用次数 : 98

The combination of transcatheter arterial chemoembolization - NCBI

www.ncbi.nlm.nih.gov/pubmed/25099027 ▾ 翻译此页

作者 : Y Chao - 2015 - 被引用次数 : 24 - 相关文章

2014年9月16日 - Int J Cancer. ... with intermediate-stage, unresectable hepatocellular carcinoma (HCC). ... TACE/sorafenib cycles were repeated every 6-8 weeks. ... administered and 52.6% of patients achieved complete response in target ...

Combination Therapy of Sorafenib and TACE for Unresectable HCC ...

www.ncbi.nlm.nih.gov > NCBI > Literature > PubMed Central (PMC) ▾ 翻译此页

作者 : L Liu - 2014 - 被引用次数 : 36 - 相关文章

2014年3月20日 - Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide ... For instance, transarterial chemoembolization (TACE) is 2% of the patients experienced a complete response (CR) according to RECIST ...

Chemoembolization of Hepatocellular Carcinoma

www.ncbi.nlm.nih.gov > NCBI > Literature > PubMed Central (PMC) ▾ 翻译此页

作者 : R Lencioni - 2013 - 被引用次数 : 45 - 相关文章

The combination of DEB-TACE and antiangiogenic therapy represents a ... Keywords: chemoembolization, hepatocellular carcinoma, transcatheter therapy ... complete response in a hepatocellular carcinoma (HCC) patient treated with ... of TACE having a beneficial effect on survival in participants with unresectable HCC